Targeted therapies: Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma
- PMID: 21360839
- DOI: 10.1038/nrclinonc.2010.208
Targeted therapies: Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma
Comment on
-
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.JAMA. 2010 Nov 17;304(19):2154-60. doi: 10.1001/jama.2010.1672. JAMA. 2010. PMID: 21081728 Clinical Trial.
References
-
- JAMA. 2010 Nov 17;304(19):2154-60 - PubMed
Publication types
LinkOut - more resources
Full Text Sources